Hepatitis C Testing in the Birth Cohort 1945-1965: Have you been tested?

Executive Summary

In July 2012, the American Academy of Nursing endorsed the recommendations of the Expert Panel on Emerging Infectious Diseases to accelerate efforts to remove barriers for hepatitis C screening and testing (Zucker, 2012). One month later the CDC announced its recommendation for the "Identification of Chronic Hepatitis C Virus Infection among Persons Born During 1945–1965." These Baby Boomers account for 76.5% of HCV cases in the United States (MMWR, 2012). Unfortunately, the stigma of injection drug use has been a major factor that has limited the success of current risk-based testing strategies (Treloar, C. & Rhodes, R. (2009). Of the estimated 2.7–3.9 million persons living with hepatitis C virus (HCV) infection in the United States, one study found that 72% of persons with a history of injection-drug use who are infected with HCV remain unaware of their infection status (Hagan, 2006). Barriers to testing include inadequate health insurance coverage and limited access to regular health care, despite having insurance coverage. Zucker (2012) previously identified the following barriers to care for patients with viral hepatitis: 1) unclear definition of "acute" HCV and how this impacts surveillance; 2) limited federal support for surveillance services and different systems for monitoring; 3) lack of a universal immunization registry; and 4) limited resources to support hepatitis A and B vaccination. Additional barriers to care have been the treatment-ineligibility of patients with significant co-morbidity, treatment that was ineffective in large numbers of patients who experience great morbidity, and the challenges of getting African Americans into treatment.

Background and Problem Identification

Although these barriers continue to pose problems, lack of education for patients with hepatitis is a significant barrier that inhibits adequate care and subsequent cure (Zeremski et al., 2013). Because the disease may be silent for a number of years, individuals are often unaware that they have HCV. Disease progression is slow, and the first signs of disease may be joint pain, jaundice, ascites, end-stage liver disease or hepatocellular carcinoma; in the latter two conditions, the prognosis is poor. To address this barrier, the U.S. Preventive Services Task Force released their recommendations to screen for HCV infection in persons at high risk for infection, and also to offer one-time screening for HCV infection to adults born between 1945 and 1965 (USPSTF, 2013). The question now is how are we doing?

The answer is that depends. While we have made little progress on addressing barriers to care, we know that recent developments in the pharmaceutical treatment of HCV with all-oral only regimens will soon be a reality. Once FDA approval of these new regimens is obtained, they will
soon replace the existing combination therapy of interferon and ribavirin. Results from clinical trials confirm excellent cure rates in genotype 1, 2 and 3 patients, and commercially developed drugs are now available (Afdhal et al., 2013). We anticipate that this year patients with significant co-morbidities will now be treated because these new drug regimens will have a lower side effect profile. However, the combination of efficient drugs for most patients and heightened government recommendations will put increased responsibility on primary care providers. Currently nurse practitioners and physician assistants manage a large proportion of HCV patients; the number of such patients will likely increase as the demand for new therapies increases and additional patients who need treatment are identified. With this revolution in treatment for persons with HCV come added responsibilities for nurses and other health care providers, consumers, and insurers.

Policy Position

Strategic goals for success in meeting these recommendations include the following:

1. Increase access to primary health care and prevention services in rural and urban settings. Barocas et al. (2014) examined barriers and facilitators to HCV screening in a large, multi-city study. Participants living in metropolitan areas and those with a primary care provider reported screening rates of 74% in the past year. Individuals living in non-urban settings without a primary care provider may experience significant barriers to screening. A successful model in Boston is using the electronic health record (EHR) to track and trigger if birth cohort patients have been tested. Surveillance data gathering and reporting varies state by state and is often inaccurate. In Massachusetts, all HCV test results from clinical laboratories are reported electronically to the Department of Public Health (DPH), however the ordering clinician has the responsibility to report positive results to the DPH.

2. Endorse patient-centered approaches that build relationships between patients and providers, thus reducing stigma. People with HCV experience stigma that can adversely affect treatment seeking and the patient provider relationship. Building trust during the clinical encounter is an important first step in reducing stigma and increasing utilization of healthcare services for people with HCV (Treloar, Rance, & Backmund, 2013).

3. Engage local, state, and national leaders who are influential in hepatitis policy, including members of Congress and the Administration using advocacy, outreach and education. A Massachusetts example has utilized key stakeholders in clinical practice and health policy to engage in lobbying activities to inform and educate members of the legislature, CMS and advocacy groups (C. Graham, personal communication, December 16, 2013).

4. Increase the visibility and awareness of hepatitis in the US by distribution of information through a variety of professional societies, advocacy groups and other relevant organizations. Social media email, and professional websites are important tools that all health care professionals can utilize to promote the CDC and USPSTF recommendations. Such activities are consistent with the strategic priorities of the National Viral Hepatitis Roundtable (National Roundtable, 2013).

Role of nurses

The role of the nurse is crucial in optimizing success in HCV screening. In a redesigned health care delivery system, nursing case management not only provides continuity of care but fosters patient advocacy (Smith, 2002). Communication of the current U.S. government recommendations, and conveying accurate and up-to-date information about hepatitis legislation, screening, testing and treatment is vital. A recent report describes how emergency department nurses used the EHR to identify all patients born 1945-65 and administered a brief pre-screening
questionnaire; eligible patients were then screened for HCV (Galbraith et al., 2013). Second is the critical role nurses play in successfully helping patients adhere to new treatment regimen. Asher, et al. (2012) have concluded that a comprehensive, multidisciplinary program including primary care, drug treatment, mental health services, HCV treatment and education as well as risk reduction counseling. Data demonstrate that nursing case management that includes education, tracking and incentives support the highest rates of patient adherence to complex treatment regimen (Nyamathi, 2009). Proven strategies for success also require an investment in resources and management systems that are implemented to increase increased quality of care coordination and are focused on a relational work space (McEvoy et al, 2011). In addition nursing surveillance has been shown to target high prevalence health problems and shortcut efforts at care management (Schoneman, 2002). A third role for nurses is to help patients manage the effects of a stigmatizing disease. The trusting relationship between nurse and patient allows patients to share their concerns and the nurse to intervene and support patient well-being (Bova et al., 2012).

Critical Next Steps

• Continue to support efforts to increase access to a broad range of primary care providers, including advanced practice registered nurses.

• Partner with other nursing organizations to disseminate educational materials and practice guidelines.

• Exploit the EHR to help identify individuals born between 1945-65 and encourage screening.

• Identify frameworks that support the importance of the patient provider relationship as a critical to patient screening and treatment and disseminate these into practice.

• Create linkages with the National Viral Hepatitis Roundtable and Primary Care Provider Groups to promote patient education and care.

• Advertise World Hepatitis Day and National Hepatitis Awareness Month activities on AAN website.

• Identify key stakeholders at the local, state, and national levels and work with these individuals to promote education of their constituents.

• Emphasize to our students, employees and interdisciplinary team members the critical role of nurses in HCV screening, referral and treatment. This includes case management, relationship building, and taking a lead role in follow through of care recommendations.

Acknowledgments

Prepared by Donna M. Zucker, PhD, RN, FAAN, and Donald E. Bailey Jr., PhD, RN, FAAN. We gratefully acknowledge the assistance provided by Dr. Andrew Muir and the Academy Emerging Infectious Diseases Expert Panel in preparing this manuscript.
References


